Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer

Translational Oncology

Volumn 6, Issue 3, 2013, Pages 338-346

  Misawa, Kiyoshi ^a   Kanazawa, Takeharu ^b   Misawa, Yuki ^a   Uehara, Takayuki ^b   Imai, Atsushi ^a   Takahashi, Goro ^a   Takebayashi, Satoru ^a   Cole, Andrew ^c   Carey, Thomas E ^c   Mineta, Hiroyuki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BISULFITE; GALANIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC RISK; GROWTH INHIBITION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 84878720705     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13115     Document Type: Article

References (38)

1. Vokes EE, Weichselbaum RR, Lippman SM, and Hong WK (1993). Head and neck cancer. N Engl J Med 328, 184-194.
2. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, et al. (2008). EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26, 3128-3137.
3. Forastiere A, Koch W, Trotti A, and Sidransky D (2001). Head and neck cancer. N Engl J Med 345, 1890-1900.
4. Hill SJ (2006). G-protein-coupled receptors: past, present and future. Br J Pharmacol 147(suppl 1), S27-S37.
5. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton JP, et al. (2007). Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 13, 6293-6300.
6. Esteller M (2008). Epigenetics in cancer. N Engl J Med 358, 1148-1159.
7. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, and Mutt V (1983). Galanin-a novel biologically active peptide from porcine intestine. FEBS Lett 164, 124-128.
8. Vrontakis ME, Torsello A, and Friesen HG (1991). Galanin. J Endocrinol Invest 14, 785-794.
9. Ottlecz A, Snyder GD, and McCann SM (1988). Regulatory role of galanin in control of hypothalamic-anterior pituitary function. Proc Natl Acad Sci USA 85, 9861-9865.
10. Bartfai T, Langel U, Bedecs K, Andell S, Land T, Gregersen S, Ahren B, Girotti P, Consolo S, Corwin R, et al. (1993). Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes. Proc Natl Acad Sci USA 90, 11287-11291.
11. Gutkind JS (1998). Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 17, 1331-1342.
12. Gundlach AL (2002). Galanin/GALP and galanin receptors: role in central control of feeding, body weight/obesity and reproduction? Eur J Pharmacol 440, 255-268.
13. Henson BS, Neubig RR, Jang I, Ogawa T, Zhang Z, Carey TE, and D'Silva NJ (2005). Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem 280, 22564-22571.
14. Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, Ueda Y, Tono T, and Carey TE (2007). Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 26, 5762-5771.
15. Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, et al. (2008). Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res 14, 7604-7613.
16. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, and Carey TE (2010). Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 32, 417-426.
17. Park NH, Min BM, Li SL, Huang MZ, Cherick HM, and Doniger J (1991). Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis 12, 1627-1631.
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, and Baylin SB (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93, 9821-9826.
19. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, and Croce CM (2003). Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63, 3724-3728.
20. Martone T, Gillio-Tos A, De Marco L, Fiano V, Maule M, Cavalot A, Garzaro M, Merletti F, and Cortesina G (2007). Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res 13, 5089-5094.
21. Park HL, Kim MS, Yamashita K, Westra W, Carvalho AL, Lee J, Jiang WW, Baek JH, Liu J, Osada M, et al. (2008). DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer 122, 2498-2502.
22. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, and Kelsey KT (2002). Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21, 4231-4236.
23. Katz MH(2011). Multivariable Analysis: A Practical Guide for Clinicians and Public Health Researchers. Cambridge University Press, Cambridge, United Kingdom.
24. Kofler B, Berger A, Santic R, Moritz K, Almer D, Tuechler C, Lang R, Emberger M, Klausegger A, Sperl W, et al. (2004). Expression of neuropeptide galanin and galanin receptors in human skin. J Invest Dermatol 122, 1050-1053.
25. Frank CJ, McClatchey KD, Devaney KO, and Carey TE (1997). Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res 57, 824-827.
26. Pearlstein RP, Benninger MS, Carey TE, Zarbo RJ, Torres FX, Rybicki BA, and Dyke DL (1998). Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 21, 333-339.
27. Takebayashi S, Ogawa T, Jung KY, Muallem A, Mineta H, Fisher SG, Grenman R, and Carey TE (2000). Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 60, 3397-3403.
28. Kanazawa T, Kommareddi PK, Iwashita T, Kumar B, Misawa K, Misawa Y, Jang I, Nair TS, Iino Y, and Carey TE (2009). Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res 15, 2222-2230.
29. Kanazawa T, Misawa K, and Carey TE (2010). Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opin Ther Targets 14, 289-302.
30. Lappano R and Maggiolini M (2011). G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10, 47-60.
31. Misawa K, Kanazawa T, Misawa Y, Imai A, Uehara T, Mochizuki D, Endo S, Takahashi G, and Mineta H (2013). Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer. J Cancer Res Clin Oncol.
32. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, et al. (2006). A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 131, 797-808.
33. Berger A, Lang R, Moritz K, Santic R, Hermann A, Sperl W, and Kofler B (2004). Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology 145, 500-507.
34. Tofighi R, Joseph B, Xia S, Xu ZQ, Hamberger B, Hokfelt T, and Ceccatelli S (2008). Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2). Proc Natl Acad Sci USA 105, 2717-2722.
35. Rodriguez-Paredes M and Esteller M (2011). Cancer epigenetics reaches mainstream oncology. Nat Med 17, 330-339.
36. Pandian GN, Shinohara K, Ohtsuki A, Nakano Y, Masafumi M, Bando T, Nagase H, Yamada Y, Watanabe A, Terada N, et al. (2011). Synthetic small molecules for epigenetic activation of pluripotency genes in mouse embryonic fibroblasts. Chembiochem 12, 2822-2828.
37. Ohtsuki A, Kimura M, Minoshima M, Suzuki T, Ikeda M, Bando T, Nagase H, Shinohara K, and Sugiyama H (2009). Synthesis and properties of PI polyamide-SAHA conjugate. Tetrahedron Lett 50, 7288-7292.
38. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, et al. (2008). DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358, 1118-1128.